Clinical Management of Children and Adolescents with Neurofibromatosis Type 1 Like Phenotypes and Complex Behavioural Manifestations: A Multidisciplinary and Dimensional Approach

Moscoso, Ana; Julien, Aurélie; Tanet, Antoine; Consoli, Angèle; Pagnard, Martine; Trevisan, France; Kemlin, Isabelle; Rodriguez, Diana; Cohen, David

doi:https://doi.org/10.1155/2019/4764031

Case Reports in Psychiatry

On this page

Abstract Background Methods Results Discussion Conclusions Conflicts of Interest Acknowledgements References Copyright Related Articles

Case Series | Open Access

Volume 2019 | Article ID 4764031 | https://doi.org/10.1155/2019/4764031

Clinical Management of Children and Adolescents with Neurofibromatosis Type 1 Like Phenotypes and Complex Behavioural Manifestations: A Multidisciplinary and Dimensional Approach

Ana Moscoso,^1,2Aurélie Julien,²Antoine Tanet,²Angèle Consoli,^2,3Martine Pagnard,²France Trevisan,²Isabelle Kemlin,⁴Diana Rodriguez,^4,5and David Cohen^2,6

Academic Editor: Erik Jönsson

Received23 May 2019

Accepted27 Nov 2019

Published31 Dec 2019

Abstract

Introduction. Cognitive and behavioural problems associated with Neurofibromatosis type 1 (NF1) are common sources of distress and the reasons behind seeking help. Here we describe patients with NF1 or NF1-like phenotypes referred to a Tier 3 Child and Adolescent Psychiatry Department and highlight the benefits of a multidisciplinary assessment. Methods. Prospective data were gathered from NF1 patients aged 7–15 years, referred by the NF1 Referral Centre due to additional difficulties either in management or diagnosis. For the selected cases, we performed a psychiatric assessment, a tailored neuropsychological evaluation based on clinical demands and history, broad speech and motor skills evaluations if there were concerns regarding language, motor abilities and/or learning difficulties and autism specific evaluations, if clinically relevant. No exclusion criteria were applied. Results. Complex NF1 cases represented only 5% of the patients (11/224). Assessments revealed the complexity of NF1 phenotype and a variety of problems including learning difficulties, emotional problems and autism spectrum disorders. Specific evaluations of language, motor, attentional and neurovisual domains were essential to guide tailored intervention strategies. Conclusions. In terms of clinical implications, the heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with complex NF1.

1. Background

Neurofibromatosis type 1 (NF1) affects approximately 1/3,000 individuals worldwide [1]. Diagnostic criteria are varied and include café-au-lait spots, neurofibromas, freckling of the axillary or inguinal regions, optic glioma, Lisch nodules, distinctive osseous lesions (such as sphenoid dysplasia or thinning of long bone cortex), as well as having a first-degree relative evidencing NF1 symptoms as detailed above [2].

Although NF1 is an autosomal dominant condition (familiar type), de novo mutations account for up to 50% of the cases (sporadic type). NF1 is completely penetrant, nonetheless it exhibits variable clinical expressivity, even between family members with the same NF1 mutation [3]. Most NF1 mutations result in reduced intracellular levels of the protein neurofibromin, leading to excessive cell proliferation, including development of neurofibromas and tumours and diminished cognitive capacity [4].

In clinical practice, cognitive and behavioural problems associated with NF1 and their impact on academic performance is a common source of distress and the reason behind seeking help in child psychiatry. Indeed, between 30% and 70% of individuals with NF1 have learning disabilities concerning speech, reading, writing, spelling and mathematics. These problems represent the most significant cause of lifetime morbidity associated with the disease [5, 6]. Even though some phenotypic patterns have been suggested in the past, a more in-depth analysis reinforces the need to tailor the diagnosis and the treatment of these patients.

The global cognitive functioning of NF1 patients is usually preserved, although somewhat lower when compared to unaffected siblings or peer groups [7]. Intellectual disability, defined clinically as an intelligence quotient (IQ) lower than 70 in cognitive evaluations, is estimated to be around 4–8% in NF1 patients vs. 2-3% in the general population [8, 9]. However, the exclusion of patients with central nervous system (CNS) pathology from cohort studies of NF1 prevalence reduces the number of patients with clinically moderate to severe NF1 [8] and may underestimate the prevalence of intellectual disability amongst this population.

For many years the Child and Adolescent Psychiatry Department of Pitié-Salpêtrière has been treating paediatric patients who present neuropsychiatric symptoms of rare diseases [10–12] as examples. As a specialised team, the department receives complex patients which present significant management issues. NF1 patients are referred to this department. Here we describe patients with NF1 received in our Departement and highlight the benefits of a multidisciplinary assessment.

2. Methods

2.1. Patients

Prospective data were gathered from NF1 patients (NIH, 1988) aged 7–15 years, referred by the Neurofibromatosis Referral Centre at Trousseau Paediatric Hospital for evaluation at the Department of Child and Adolescent Psychiatry at University Hospital La Pitié-Salpêtrière. The data spans from 2009 until 2016. The procedures regarding the assessments and follow-ups at the Referral Centre are described elsewhere [13]. Referrals were made due to additional difficulties either in management or diagnosis of patients and represented only a small part of the cohort (11/224—approximately 5%). No exclusion criteria were applied as we wanted to describe all complex aspects of this clinical sub sample.

2.2. Procedures and Instruments

Patients were assessed in medical consultations and further comprehensive evaluations. For the selected cases, we extracted from the prospective database: sociodemographic data (age, sex, academic level); all relevant information from the semi-structured medical interview to evaluate the patient’s personality and family history of psychiatric and medical disorders, including NF1 clinical features, complications and follow-ups; and all relevant biological (e.g. genetic testing), physiological (e.g. electro-encephalography) and imaging (e.g. magnetic resonance imaging) information. In addition, we performed (1) a psychiatric assessment; (2) a tailored neuropsychological evaluation (e.g. executive function, attention, memory, neurovisual) based on clinical demands and history; (3) a broad speech evaluation, if there were language (oral and/or written) concerns or learning difficulties; (4) a global and fine motor skills evaluation, if there were concerns regarding motor abilities and/or learning difficulties (such as difficulties to write), and (5) autism specific evaluations, if clinically relevant. The list of testing is given in Tables 1 and 2.

Evaluations were performed because they had clinical relevance. They were adapted to the needs and characteristics of each patient. Medical files containing clinical data were thoroughly explored (AM, AJ, MP) and relevant data were included (AM, AJ, AT, MP). Psychiatric diagnoses were made according to DSM-5 criteria. Finally, the scores obtained in neuropsychological, speech and fine motor skills assessments were converted into standard deviations in order to have unique common statistics and to ease presentation.

3. Results

Eleven patients were included. All, except one, were boys with a mean age of 10.6 (range 7–15) years. Five patients had a first degree relative with NF1 (father, mother or sibling). Two patients lived in foster care and five with one parent (due to divorce). One had Legius syndrome, a genetic condition associated with sprouty related EVH1 domain containing 1 (SPREAD1) gene mutation, which phenotype overlaps that of NF1 [14]. For clarity, we present the patients in two separate tables. Table 1 summarises the clinical profile of four NF1 patients with an intellectual deficiency and Table 2 presents the profile of patients with subnormal IQ.

3.1. Reasons for Referral

Patients came with multiple and diverse complaints. Reasons for referral included learning difficulties (due to the consequences of instrumental difficulties, suspicion of attention deficit hyperactivity disorder (ADHD) or intellectual disability; ), or emotional problems or suspicion of emergent psychopathology (). A few () were referred because of autism spectrum disorder (ASD) (doubts regarding diagnosis or difficulties in clinical management).

3.2. NF1 Clinical Characteristics and Intellectual Impairment

Clinical complications of NF1 (skeletal, vascular, malignancy, epilepsy, precocious puberty, the presence of unidentified bright objects (UBOs) in CNS) were present in patients who also had a certain degree of intellectual disability (Table 1), sometimes accompanied by autistic features (patients 1, 2, 4; Table 1). Only, one patient with NF1 complications did not present with an intellectual disability but had a borderline IQ (patient 8; Table 2). In four patients, UBOs were present mainly in the cerebellum and the basal ganglia (patients 1, 2, 4 and 8). NF1 complications motivated frequent medical appointments and hospitalisations, an additional burden for patients and their families. For all the other patients (Table 2) only mild NF1 features, such as café-au-laits spots, intertriginous freckling, few neurofibromas and/or Lisch nodules, were present. These patients all had subnormal IQ.

3.3. NF1 and Learning Disabilities

All patients had learning disabilities that appeared as a primary or secondary cause of referral. For the patients who had subnormal IQ scores (Table 2), it was common to find discrepancies in IQ sub-scales. Within each subscale, scores could vary widely (data not shown). Even if the patients received an average/mean IQ, their global intellectual efficiency was weaker when compared to the general population.

Specific learning disabilities were also common. They included specific language developmental delays (patients 5, 6, 9, 11; Table 2), graphomotor delays (patients 5, 6, 7, 8; Table 2) and developmental coordination disorders (dyspraxia) (patients 8, 9; Table 2). Some patients also had comorbid ADHD (patients 5, 6, 8; Table 2). The extensive developmental evaluation was crucial to disentangle diagnosis and also to guide further therapeutic propositions. Such specific propositions included school adaptations (such as having more time to finish evaluations, the use of computer to write), speech and reading therapies once or twice per week, and motor skills remediation once per week, that lead to improvement (nonpharmacological treatment; Table 2).

Patients with intellectual disabilities (Table 1) arguably presented learning difficulties. Standard tests for cognitive evaluation (such as the Wechsler intelligence scale for children, WISC [29]) were difficult to perform in such patients. In these cases, clinical evaluation and developmental scales were helpful (Brunet Lezine [18]), Terman Merrill [25]), as well as some psychosocial scales (Psychoeducational Profile (PEP) [23], Vineland [28]) that estimate performance in more ecologic day to day activities. In this context, specific evaluations of language, motor, and attentional domains are equally important to guide tailored intervention strategies. Intervention strategies were generally more global in the context of schooling for disabled children.

3.4. NF1 and Attentional Issues

Four of our patients had an ADHD diagnosis, obtained after clinical assessment and a specific neuropsychological evaluation (Test of Everyday Attention for Children, TEA-Ch [24]). A fifth patient (patient 4; Table 1) diagnosed with ADHD was evaluated through clinical observation and functional scales (Conners [20]), because the neuropsychological evaluation was difficult to perform given the intellectual deficit. In all cases, an ADHD diagnosis was made along with other comorbidities and was never isolated. Four patients were treated with methylphenidate and one was given specific cognitive training addressing attention. Three patients receiving methylphenidate improved and one stopped the treatment due to side effects.

3.5. NF1, Emotional Problems and Emergent Psychopathology

The most frequent diagnosis was anxiety disorder and/or NF1 related stress (patients 1, 4, 7, 10, 11). Two visited for the evaluation and treatment of mood disturbances (patients 8, 11; Table 2). Finally, another patient visited for psychiatric evaluation in the context of sexual assault (patient 3; Table 1). Medication along with nonpharmacological treatments such as different types of psychotherapy were proposed and appeared to be helpful.

3.6. NF1 and Autistic Spectrum Symptomatology

Four patients presented clear autistic features after clinically comprehensive/developmental assessment and additional assessment tools (patients 1, 2, 4; Table 1 and patient 9, Table 2). Three patients with autistic features had concurrent intellectual disability (Table 1). A fifth patient with an ongoing history of social difficulties had a pragmatic communication disorder (patient 5; Table 2). Complementary psychological tests were helpful for the diagnosis (CARS [19], ADI [15], ADOS [16]). Treatment strategies addressed co-morbidities as well as core features of autism (e.g., social strategies in group) in outpatient settings or in the context of specific schooling models.

4. Discussion

This case series reflects the variety of problems and the complexity of severe NF1 paediatric patients. The gender bias reflected in our sample may result from the overrepresentation of boys in child and adolescent psychiatry consultations and therefore will not necessarily reflect the epidemiology of NF1 [30]. Also, the morbimortality of the disease, is mild to moderate in most cases. Nonetheless, clinical complications of NF1 can present a serious burden. This was the case for most of the patients reported here, who were referred to a special psychiatric clinic for rare diseases. The large heterogeneous phenotypic expression of NF1 is likely to be a consequence of the stochastics chain of events associated with NF1. At a molecular level, the reduced intracellular levels of neurofibromin found in NF1 patients induce impairments in learning and memory through imprecise, i.e. abnormally high or low RAS modulation and consequential gamma-aminobutyric acid (GABA)-mediated excessive inhibition in the hippocampus [4, 31]. Also, patients with NF1 may show subcortical unidentified bright objects (UBOs) as we found in four of our patients. In all but one, UBOs were present in patients with intellectual disability and a multitude of somatic complications of the disease. UBOs are present in approximately 60–70% [32, 33] of the children with NF1 but tend to disappear with age. Histopathologic studies have shown that UBOs correspond to areas of myelin vacuolization with increased water content [34] and therefore, could reflect disordered myelination [35]. The presence of UBOs has been associated with lower intellectual ability [36, 37] and also visuospatial impairments when UBOs were located in the cerebellum [38]. The latter seems to be the case for patients 1 and 2 (Table 1) and patient 8 (Table 2) in our case series.

4.1. NF1 Cognitive Impairment and Learning Disabilities

In this case series, the patients presented either a degree of intellectual disability (Table 1) or an average but heterogeneous cognitive profile with significant functional impairments (Table 2). Many studies have now made clear how intelligence is only mildly affected in the vast majority of NF1 patients. However, specific impairments in cognition are very common (up to 80% of children in NF1 clinics [8]) and have a negative impact in the quality of life. Some specific deficits have been reported to NF1: visual-spatial deficits [39], speech and language deficits, motor skill deficits [40], social skill deficits [5, 41] and attentional deficits [8, 42]. All may lead to learning disabilities and further emotional suffering. The presence of visual-spatial and attentional deficits has been robustly replicated [7, 43]. However, research has revealed contradictory results regarding motor skills and language performance in patients with NF1 [7]. Moderate to severe intellectual disability and severe clinical cases seemed to be the focus of interest of early works in neurofibromatosis [44] but severe cases of NF1 have received little attention recently.

4.2. NF1 and ADHD

In all our NF1-ADHD patients, the ADHD diagnosis was made along with other comorbidities and was never isolated. Patients with NF1 present more symptoms and are more often diagnosed with ADHD than the general population. Prevalence estimates range from 30% to 50% [45, 46], which are higher than those expected in the general population, i.e. about 5% in children and 2.5% in adults [47, 48].

Clinical and cognitive profiles of both ADHD patients with and without NF1 are heterogeneous. Individuals are affected in different domains of attention, impulsivity, hyperactivity and executive functioning, and to different degrees [46, 49]. Visual attention seems consistently impaired in NF1 patients [50, 51] and would lead to instability in focusing attention and lower resistance to interference in controlled tasks but also to inattentive and impulsive behaviour in natural environments.

Importantly, ADHD-NF1 patients seem responsive to methylphenidate [42, 46]. This improvement has been also reported for children with IQs lower than 80 [46]. In our case series, four of the patients diagnosed with ADHD were treated with methylphenidate, three showing a great improvement and one dropping out of treatment due to side effects.

The high frequency of ADHD in children with NF1, as well as the demonstrated significant comorbidity of ADHD with literacy learning disabilities [8] and social skills problems [52] indicates the need for thorough screening of ADHD symptomatology in all children with NF1 [45]. Besides, the impact of attention deficits and behaviour problems in children with NF1 often leads to lower social acceptance and lack of self-confidence/esteem. When emotional problems are secondary to ADHD, effective treatment of ADHD can improve them both [46].

4.3. NF1 and Autistic Spectrum Symptomatology

After some early work evoking associations between autism and NF1 [53] there is a re-enacted concern regarding ASD and NF1. Since Huijbregts and de Sonneville [54] showed that NF1 impairments in cognitive control (i.e. a combination of processing speed, working memory, inhibitory control, and emotional processing functions) is associated with the presence of autistic traits, several studies have explored the prevalence of ASD symptoms in NF1 populations.

Studies focusing on social impairments as a continuous variable within the social responsiveness scale (SRS) [55–58] showed that NF1 patients present more social impairments than the general population (up to 40% in some samples [56]). Whether or not this is enough to state that ASD is increased in NF1 patients is another question. First, ASD screening tools are not meant to provide a diagnosis of ASD, but rather identify children who should be further evaluated. Second, NF1 patients with high SRS scores show mild to moderate ASD symptomatology (e.g. latter diagnosis during school years; no stereotyped behaviours) [57]. We believe that research should explore further the meaning of ASD symptomatology in NF1. Given the rarity of stereotyped behaviours in NF1, perhaps the DSM-5 diagnosis of social communication disorder will be more appropriate in some cases? Also, is it legitimate to use SRS score as a continuous variable? Indeed, when re-analysing the largest cohort of NF1 so far that reported SRS scores [59] we found that the best model to predict data distribution using admixture analysis was a bimodal distribution (Figure 1), with a large group of patients with a mean SRS score equal to 55 (red curve), and a smaller group of patients with a higher mean SRS score equal to 70 (green curve). This means that considering SRS as a continuous variable showing a normal distribution may be inappropriate. This also means that NF1 phenotype heterogeneity might be better understood separating subgroups of patients as it has been shown in other genetically complex neurodevelopmental disorders.

However, we do believe that rare typical cases of ASD can also be encountered in NF1. Three patients in this case series presented an unequivocal profile of ASD comorbid with intellectual disability. Several authors postulated that autism associated with neurogenetic syndromes can be classified as “complex autism” or “syndromic autism” [60–62]. Complex autism is characterised by lower IQ, higher rates of comorbidities both psychiatric and somatic, and higher rates of epilepsy [63, 64]. For these severe cases, this classification may be useful to better explore their clinical profile and tailor treatment to the child’s needs [65].

4.4. NF1 and Emotional Problems

NF1 has also significant social and psychological consequences on individuals and their families [66, 67]. Most patients of this case series were referred with emotional problems. While some () had behavioural difficulties (sometimes secondary to ADHD or to learning disabilities), others expressed internalising symptoms such as anxiety or depression. These conditions can often be found in NF1 [67]. The emotional impact of cosmetic deformities, the fear of malignancy, and the medical complications, such as the management of hypertension or the need for surgical interventions should be carefully evaluated and not be neglected. Learning difficulties can also generate feelings of low self-esteem and inefficiency that can last in time. In addition, the impact of attention deficits and behaviour problems in children with NF1 often leads to lower social acceptance and lack of self-confidence. As mentioned previously, when emotional problems are secondary to ADHD, effective treatment of ADHD can improve them both [46]. Besides, parents of NF1 children experience greater stress than other parents [68], sometimes associated with feelings of guilt regarding the genetic transmission of NF1. The parents should also receive proper care.

4.5. Treatment Modalities and Outcome

Strategies that decrease either RAS activity or GABA-mediated inhibition have been suggested to specifically treat learning and emotional deficits associated with NF1. Pharmacologically targeting this pathway with an HMG-CoA reductase inhibitor (an anti-RAS agent), such as lovastatin [69] evidenced some encouraging results in animal models. However, to date, clinical trials with NF1 patients have shown modest results [70–72]. Therefore, current treatment options remain symptomatic. The heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with NF1. The outcome is therefore variable, different for each patient.

5. Conclusions

In severe cases of NF1 with important psychiatric morbidity, it can sometimes be difficult to disentangle specific domains of impairment, as cognition as a whole is complex. In day-to-day activities, more than one cognitive domain is needed to perform adequately, making the task of disentanglement even more challenging. This is why a multidimensional and longitudinal clinical evaluation is warranted when assessing patients.

Phenotype-genotype correlations tend to subscribe the idea that behavioural manifestations present themselves with continuous variation. This type of pattern was proposed for NF1 autistic symptoms [59]. However, we believe that more complex phenotype/genotype association occurs in NF1 for psychiatric comorbidity including ASD symptomatology. Similarly to other genetic conditions such as juvenile myotonic dystrophy [73], or tuberous sclerosis [74], bimodal phenotypic patterns of intelligence/cognitive performance seem to adapt better to the distribution of IQ scores in these populations. In terms of clinical implications, the heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with NF1.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgements

The authors wish to thank Joana Queiroz for the English language-editing.

References

J. M. Friedman, “Epidemiology of neurofibromatosis type,” American Journal of Medical Genetics, vol. 89, no. 1, pp. 1–6, 1999.
View at: Publisher Site | Google Scholar
D. A. Stumpf, “Neurofibromatosis. conference statement, national institutes of health consensus development conference,” Archives of Neurology, vol. 45, no. 5, pp. 575–578, 1988.
View at: Google Scholar
K. P. Boyd, B. R. Korf, and A. Theos, “Neurofibromatosis type 1,” Journal of the American Academy of Dermatology, vol. 61, pp. 1–16, 2009.
View at: Publisher Site | Google Scholar
R. M. Costa, N. B. Federov, J. H. Kogan et al., “Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1,” Nature, vol. 415, no. 6871, pp. 526–530, 2002.
View at: Google Scholar
S. R. Plotkin, A. C. Albers, D. Babovic-Vuksanovic et al., “Update from the 2013 international neurofibromatosis conference,” American Journal of Medical Genetics. Part A, vol. 164, no. 12, pp. 2969–2978, 2014.
View at: Publisher Site | Google Scholar
J. C. Isenberg, A. Templer, F. Gao, J. B. Titus, and D. H. Gutmann, “Attention skills in children with neurofibromatosis type 1,” Journal of Child Neurology, vol. 28, no. 1, pp. 45–49, 2013.
View at: Publisher Site | Google Scholar
A. Lehtonen, E. Howie, D. Trump, and S. M. Huson, “Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence,” Developmental Medicine and Child Neurology, vol. 55, no. 2, pp. 111–125, 2012.
View at: Publisher Site | Google Scholar
S. L. Hyman, A. Shores, and K. N. North, “The nature and frequency of cognitive deficits in children with neurofibromatosis type 1,” Neurology, vol. 65, no. 7, pp. 1037–1044, 2005.
View at: Publisher Site | Google Scholar
R. E. Ferner, R. A. Hughes, and J. Weinman, “Intellectual impairment in neurofibromatosis 1,” Journal of the Neurological Sciences, vol. 138, no. 1-2, pp. 125–133, 1996.
View at: Publisher Site | Google Scholar
M. Douniol, A. Jacquette, D. Cohen et al., “Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1 includes internalising disorder, borderline intelligence, visual spatial construction disability and attention deficit disorder,” Developmental Medicine and Child Neurology, vol. 54, no. 10, pp. 905–911, 2012.
View at: Publisher Site | Google Scholar
O. Bonnot, D. Cohen, D. Thuilleaux, A. Consoli, S. Cabal-Berthoumieu, and M. T. Tauber, “Psychotropic treatments in Prader Willi syndrome: a critical review of published literature,” European Journal of Pediatrics, vol. 175, no. 1, pp. 9–18, 2016.
View at: Publisher Site | Google Scholar
A. Consoli, M. Raffin, C. Laurent et al., “Medical and developmental risk factors of catatonia in children and adolescents: a 17-year prospective study,” Schizophrenia Research, vol. 137, pp. 151–158, 2012.
View at: Publisher Site | Google Scholar
V. Coutinho, H. Câmara-Costa, I. Kemlin, T. Bilette de Villemeur, D. Rodriguez, and G. Dellatolas, “The discrepancy between performance-based measures and questionnaires when assessing clinical outcomes and quality of life in pediatric patients with neurological disorders,” Applied Neuropsychology: Child, vol. 6, no. 4, pp. 255–261, 2017.
View at: Publisher Site | Google Scholar
G. Spurlock, E. Bennett, N. Chuzhanova et al., “SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype,” Journal of Medical Genetics, vol. 46, no. 7, pp. 431–437, 2009.
View at: Publisher Site | Google Scholar
Le Couteur, A. C. Lord, and M. Rutter, Autism Diagnostic Interview-Revised (ADI-R). Autism Genetic Resource Exchange, ADI-R, Los Angeles, CA, 2003.
C. Lord, M. Rutter, S. Goode et al., “Autism diagnostic observation schedule: a standardized observation of communicative and social behavior,” Journal of Autism and Developmental Disorders, vol. 19, no. 2, pp. 185–212, 1989.
View at: Publisher Site | Google Scholar
E. Hamstra-Bletz, J. D. Bie, and B. D. Brinker, “BHK—concise evaluation scale for children handwriting,” Beknopte Beoordelingsmethode Voor Kinderhandschriften (Une Méthode Rapide dévaluation De L’écriture Chez L’enfant, Swets & Zeitlinger, Lisse, 1987.
View at: Google Scholar
O. Brunet, I. Lézine, and D. Josse, “Le développement psychologique de la première enfance 1951. Nouvelle version révisée,” Echelle de Développement Psychomoteur De La Première Enfance, E.A.P, PUF, Paris, 1997.
View at: Google Scholar
E. Schopler, R. J. Reichler, and B. R. Renner, The Childhood Autism Rating Scale1937, Western Psychological Services, Los Angeles, 1988.
C. K. Conners, Conners’ Continuous Performance Test Version 5, Pearson Canada Assessment, Toronto, 2 edition, 2004.
M. P. Thibault, M. Lenfant, and M. C. Helloin, “Bilan informatisé pour l’examen du langage et des compétences transversales chez l’enfant de 8 à 11 ans (ou scolarisé du CE2 au CM2),” 2003.
View at: Google Scholar
M. Korkman, U. Kirk, and S. Kemp, NEPSY-II: Bilan Neuropsychologique De L’enfant [Neuropsychological Test for Children]. Bilan Neuropsychologique de l’Enfant (NEPSY), Edition du Centre de Psychologie Appliqué, Paris, 2 edition, 2012.
E. Schopler, R. J. Reichler, A. Bashford, M. D. Lansing, and L. M. Marcus, “Individual Assessment and Treatment for Autistic and Developmentally Disabled Children: Vol. 1.,” in Psychoeducational Profile Revised PEP, Pro-Ed, USA, Austin, 3 edition, 1990.
View at: Google Scholar
T. Manly, V. Anderson, I. Nimmo-Smith, A. Turner, P. Watson, and I. H. Robertson, “The differential assessment of children’s attention: the test of everyday attention for children (TEA-Ch), normative sample and ADHD performance,” Journal of Child Psychology and Psychiatry, vol. 42, no. 8, pp. 1065–1081, 2001.
View at: Publisher Site | Google Scholar
L. M. Terman, M. A. Merrill, and R. Samuel, Stanford–Binet Intelligence Scale: Manual for the Third Revision Form L-M with Revised IQ Tables, Houghton Mifflin, Pinneau. Boston (MA), 1960.
P. Wallon and C. Mesmin, Test, de la figure complexe de Rey (Rey–Osterrieth complex figure): A. Rey Test de la figure complexe de Rey, Edition du Centre de Psychologie Appliqué, Paris, 2009.
F. Pons, P. L. Harris, and M. de Rosnay, “Emotional comprehension between 3 and 11 years: developmental periods and hierarchical organization,” European Journal of Developmental Psychology, vol. 1, no. 2, pp. 127–152, 2004.
View at: Publisher Site | Google Scholar
S. S. Sparrow, D. A. Balla, D. V. Cicchetti, G. Balboni, and L. Pedrabissi, “Vineland Adaptive Behaviour Scales,” in Circle Pines, MN: American Guidance Service, O.S., Florence, 2003.
View at: Google Scholar
D. Wechsler, The Wechsler Intelligence Scale for Children—Fourth Edition, Pearson, London, 2003.
H. C. Steinhause, “Child and adolescent psychiatric disorders in a public service over seventy years,” European Child and Adolescent Psychiatry, vol. 6, no. 1, pp. 42–48, 1997.
View at: Publisher Site | Google Scholar
C. Li, Y. Cheng, D. A. Gutmann, and D. Mangoura, “Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons,” Developmental Brain Research, vol. 130, no. 2, pp. 231–248, 2001.
View at: Publisher Site | Google Scholar
S. L. Hyman, D. S. Gill, E. A. Shores, A. Steinberg, and K. North, “T2-Hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, pp. 1088–1091, 2007.
View at: Publisher Site | Google Scholar
J. R. Lopes Ferraz Filho, M. P. Munis, A. Soares Souza, R. A. Sanches, E. M. Goloni-Bertollo, and E. C. Pavarino-Bertelli, “Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1,” Pediatric Radiology, vol. 38, no. 3, pp. 305–310, 2008.
View at: Publisher Site | Google Scholar
D. P. DiPaolo, R. A. Zimmerman, L. B. Rorke, E. H. Zackai, L. T. Bilaniuk, and A. T. Yachnis, “Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain,” Radiology, vol. 195, no. 3, pp. 721–724, 1995.
View at: Publisher Site | Google Scholar
R. J. Sevick, A. J. Barkovich, M. S. Edwards, T. Koch, B. Berg, and T. Lempert, “Evolution of white matter lesions in neurofibromatosis type 1: MR findings,” AJR. American Journal Roentgenology, vol. 159, no. 1, pp. 171–175, 1992.
View at: Publisher Site | Google Scholar
P. Joy, C. Roberts, K. North, and M. de Silva, “Neuropsychological function and MRI abnormalities in neurofibromatosis type 1,” Developmental Medicine and Child Neurology, vol. 37, no. 10, pp. 906–914, 1995.
View at: Publisher Site | Google Scholar
J. M. Payne, T. Pickering, M. Porter et al., “Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study,” American Journal of Medical Genetics. Part A, vol. 164, no. 3, pp. 661–665, 2014.
View at: Publisher Site | Google Scholar
O. Piscitelli, M. C. Digilio, R. Capolino, D. Longo, and V. Di Ciommo, “Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning,” Developmental Medicine and Child Neurology, vol. 54, no. 1, pp. 49–51, 2012.
View at: Publisher Site | Google Scholar
K. North, “Neurofibromatosis type 1,” American Journal of Medical Genetics, vol. 97, no. 2, pp. 119–127, 2000.
View at: Publisher Site | Google Scholar
A. B. Rietman, R. Oostenbrink, S. Bongers et al., “Motor problems in children with neurofibromatosis type 1,” Journal of Neurodevelopmental Disorders, vol. 19, no. 9, p. 19, 2017.
View at: Publisher Site | Google Scholar
E. I. Pierpont, R. L. Hudock, A. M. Foy et al., “Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1,” Journal of Neurodevelopmental Disorders, vol. 10, no. 1, p. 21, 2018.
View at: Publisher Site | Google Scholar
L. Lion-François, F. Gueyffier, C. Mercier et al., “The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial,” Orphanet Journal of Rare Disorders, vol. 9, no. 1, p. 142, 2014.
View at: Publisher Site | Google Scholar
K. Lidzba, S. Granström, J. Lindenau, and V. F. Mautner, “The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1,” Developmental Medicine and Child Neurology, vol. 54, no. 10, pp. 892–897, 2012.
View at: Publisher Site | Google Scholar
N. Pinsard, M. Rufo, F. Giraud, and R. Bernard, “Mental retardation and Recklinghausen’s neurofibromatosis,” Journal de Genetique Humaine, vol. 23, pp. 228-229, 1975.
View at: Google Scholar
J. Payne, S. Hyman, E. Shores, and K. North, “Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behaviour,” Child Neuropsychology, vol. 17, no. 4, pp. 313–329, 2011.
View at: Publisher Site | Google Scholar
V. F. Mautner, L. Kluwe, S. D. Thakker, and R. A. Leark, “Treatment of ADHD in neurofibromatosis type 1,” Developmental Medicine and Child Neurology, vol. 44, no. 3, pp. 164–170, 2002.
View at: Publisher Site | Google Scholar
G. Polanczyk, M. S. de Lima, B. L. Horta, J. Biederman, and L. A. Rohde, “The worldwide prevalence of ADHD: a systematic review and metaregression analysis,” American Journal of Psychiatry, vol. 164, no. 6, pp. 942–948, 2007.
View at: Publisher Site | Google Scholar
V. Simon, P. Czobor, S. Bálint, A. Mészáros, and I. Bitter, “Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis,” British Journal of Psychiatry, vol. 194, no. 3, pp. 204–211, 2009.
View at: Publisher Site | Google Scholar
L. J. Seidman, “Neuropsychological functioning in people with ADHD across the lifespan,” Clinical Psychology Review, vol. 26, no. 4, pp. 466–485, 2006.
View at: Publisher Site | Google Scholar
G. Michael, S. Garcia, V. Herbillon, and L. Lion-François, “Reactivity to visual signals in neurofibromatosis type 1: is everything ok?” Neuropsychology, vol. 28, no. 3, pp. 423–428, 2014.
View at: Publisher Site | Google Scholar
M. J. Ribeiro, O. C. D’Almeida, F. Ramos, J. Saraiva, E. D. Silva, and M. Castelo-Branco, “Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits,” Journal of Neurodevelopmental Disorders, vol. 6, no. 1, p. 4, 2014.
View at: Google Scholar
B. Barton and K. North, “Social skills of children with neurofibromatosis type 1,” Developmental Medicine and Child Neurology, vol. 46, no. 8, pp. 553–563, 2004.
View at: Publisher Site | Google Scholar
O. Mbarek, S. Marouillat, J. Martineau, C. Barthélémy, J.‐P. Müh, and C. Andres, “Association study of the NF1 gene and autistic disorder,” American Journal of Medical Genetics, vol. 88, no. 6, pp. 729–732, 1999.
View at: Publisher Site | Google Scholar
S. C. Huijbregts and L. M. de Sonneville, “Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1?” Behavior Genetics, vol. 41, no. 3, pp. 430–436, 2011.
View at: Publisher Site | Google Scholar
S. Garg, A. Lehtonen, S. M. Huson et al., “Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study,” Developmental Medicine and Child Neurology, vol. 55, no. 2, pp. 139–145, 2013.
View at: Publisher Site | Google Scholar
K. S. Walsh, J. I. Vélez, P. G. Kardel et al., “Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1,” Developmental Medicine and Child Neurology, vol. 55, no. 2, pp. 131–138, 2013.
View at: Publisher Site | Google Scholar
E. Plasschaert, M. J. Descheemaeker, L. Van Eylen, I. Noens, J. Steyaert, and E. Legius, “Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1,” American Journal of Medical Genetics Part B, Neuropsychiatric genetics, vol. 168, no. 1, pp. 72–80, 2015.
View at: Publisher Site | Google Scholar
J. Tinker, P. S. Carbone, D. Viskochil, A. Mathiesen, K. N. Ma, and D. A. Stevenson, “Screening children with neurofibromatosis type 1 for autism spectrum disorder,” American Journal of Medical Genetics. Part A, vol. 164, pp. 1706–1712, 2014.
View at: Publisher Site | Google Scholar
S. M. Morris, M. T. Acosta, S. Garg et al., “Disease burden and symptom structure of autism in neurofibromatosis type 1,” JAMA Psychiatry, vol. 73, no. 12, pp. 1276–1284, 2016.
View at: Publisher Site | Google Scholar
J. Miles, T. Takahashi, S. Bagby et al., “Essential versus complex autism: Definition of fundamental prognostic subtypes,” American Journal of Medical Genetics Part A, vol. 135, no. 2, pp. 171–180, 2005.
View at: Publisher Site | Google Scholar
A. M. Van Eeghen, M. B. Pulsifer, V. L. Merker et al., “Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach,” Developmental Medicine and Child Neurology, vol. 55, no. 2, pp. 146–153, 2013.
View at: Publisher Site | Google Scholar
D. Cohen, N. Pichard, S. Tordjman et al., “Specific genetic disorders and autism: clinical contribution towards their identification,” Journal of Autism and Developmental Disorders, vol. 35, no. 1, pp. 103–116, 2005.
View at: Publisher Site | Google Scholar
C. Amiet, I. Gourfinkel-An, A. Bouzamondo et al., “Epilepsy in autism is associated with mental retardation and gender: evidence from a meta-analysis,” Biological Psychiatry, vol. 64, no. 7, pp. 577–582, 2008.
View at: Publisher Site | Google Scholar
C. Amiet, I. Gourfinkel-An, C. Laurent et al., “Epilepsy in multiplex autism pedigrees is associated with intellectual disability and known genetic and nongenetic causes, but not with gender,” Molecular Autism, vol. 4, no. 1, p. 47, 2013.
View at: Publisher Site | Google Scholar
J. Xavier, C. Bursztejn, M. Stiskin, and D. Cohen, “Autism spectrum disorders: A developmental and dimensional approach toward a tailored therapeutic program,” Research in Autism Spectrum Disorder, vol. 18, pp. 21–33, 2015.
View at: Publisher Site | Google Scholar
C. M. Benjamin, A. Colley, D. Donnai, H. Kingston, R. Harris, and L. Kerzin-Storrar, “Neurofibromatosis type 1 (NF1) knowledge, experience and reproductive decisions of affected patients and families,” Journal of Medical Genetics, vol. 30, no. 7, pp. 567–574, 1993.
View at: Publisher Site | Google Scholar
K. North, J. M. Friedman, G. H. Gutmann, M. MacCollin, and V. Riccardi, “Cognitive function and academic performance,” in In Neurofibromatosis: Phenotype, Natural History and Pathogenesis, p. 380, John Hopkins University Press, Baltimore, 3rd edition, 1999.
View at: Google Scholar
M. Esposito, R. Marotta, M. Roccella et al., “Pediatric neurofibromatosis 1 and parental stress: a multicenter study,” Neuropsychiatric Disease Treatment, vol. 10, pp. 141–146, 2014.
View at: Publisher Site | Google Scholar
W. Li, Y. Cui, S. A. Kushner et al., “The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1,” Current Biology, vol. 15, no. 21, pp. 1961–1967, 2005.
View at: Publisher Site | Google Scholar
C. E. Bearden, G. S. Hellemann, T. Rosser et al., “A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I,” Annals of Clinical and Translational Neurology, vol. 3, no. 4, pp. 266–279, 2016.
View at: Publisher Site | Google Scholar
L. C. Krab, A. de Goede-Bolder, F. K. Aarsen et al., “Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial,” The Journal of the American Medical Association, vol. 300, no. 3, pp. 287–294, 2008.
View at: Publisher Site | Google Scholar
T. van der Vaart, E. Plasschaert, A. B. Rietman et al., “Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial,” Lancet Neurology, vol. 12, no. 11, pp. 1076–1083, 2013.
View at: Publisher Site | Google Scholar
M. Douniol, A. Jacquette, J. M. Guilé et al., “Psychiatric and cognitive phénotype in children and adolescents with myotonic dystrophy,” European Child and Adolescent Psychiatry, vol. 18, pp. 705–715, 2008.
View at: Google Scholar
P. J. De Vries and P. F. Bolton, “Genotype-phenotype correlations in tuberous sclerosis,” Journal of Medical Genetics, vol. 37, no. 5, e3 pages, 2000.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2019 Ana Moscoso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1481

Downloads

1201

Citations